Antiplatelet Agents for Stroke Prevention |
| |
Authors: | Samuel Yip Oscar Benavente |
| |
Institution: | 1.Division of Neurology, Brain Research Centre,University of British Columbia, Stroke Program,Vancouver,Canada |
| |
Abstract: | Stroke is one of the leading causes of disability and death. Ischemic stroke is a syndrome with heterogeneous mechanisms and
multiple etiologies, rather than a singularly defined disease. Approximately one third of ischemic strokes are preceded by
another cerebrovascular ischemic event. Stroke survivors are at high risk of vascular events (i.e., cerebrovascular and cardiovascular
events), particularly during the first several months after the ischemic event. The use of antiplatelet agents remains the
fundamental component of secondary stroke prevention. Based on the available data, antiplatelet agents should be used for
patients with noncardioembolic stroke. The use of combination therapy (aspirin plus clopidogrel) has not been proven to be
effective or safe to use for prevention of early stroke recurrence or in long-term treatment. There is no convincing evidence
that any of the available antiplatelet agents are superior for a given stroke subtype. Currently, the uses of aspirin, clopidogrel,
or aspirin combined with extended release dipyridamole are all valid alternatives after an ischemic stroke or transient ischemic
attack. However, to maximize the effects of these agents, the treatment should be initiated as early as possible and be continued
on a lifelong basis. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|